Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro
Up to 12% of endometrial cancers are ultra-mutated secondary to polymerase-ε (POLE) mutations. POLE (+) tumors are heavily infiltrated with CD4 +/CD8 + TIL and overexpress PD1 immune-check-point. POLE ultra-mutated tumors are more resistant to platinum chemotherapy.